Innovative Thermobalancing therapy can help millions of men with enlarged prostate gland to improve the quality of life and well-being throughout the world

Millions of men across the world suffer from enlarged prostate or benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms (LUTS). Medications and surgical procedures for BPH have serious side effects, reducing quality of life and wellbeing. 10 years empirical evidence and outcomes of a clinical study have shown effectiveness of innovative Thermobalancing therapy (TT) with Dr Allen’s therapeutic device (DATD) to treat the cause of BPH. Dynamics of urinary symptoms by International Prostate Symptom Score, quality of life (QoL), ultrasound prostate volume (PV mL) and uroflowmetry (maximum flow rate, Qmax mL/s) were evaluated at the beginning and end of the study in 124 patients who received TT for 6 months, comparing with no-treatment group. TT has diminished PV from 45 mL to 31 mL (P<0.001) and the urinary symptoms from 14.2 to 4.9 (P<0.001), increased Qmax 8.1 to 17.7 mL/s (P<0.001) and improved QoL from 3.9 to 1.3(P<0.001). Thus, the obtained data explores the substantial positive changes in PV and urine flow rate and, consequently, the significant improvement of urinary symptoms and QoL after use of TT with DATD as mono-therapy. Given the lack of side effects after use of DATD, which should be expected after BPH drugs and operations, it should be stated that TT should be used worldwide as first line treatment for men with LUTS due to BPH to improve men’s health and wellbeing.